Octagon Capital Advisors LP Viridian Therapeutics, Inc.\De Transaction History
Octagon Capital Advisors LP
- $449 Million
- Q4 2024
A detailed history of Octagon Capital Advisors LP transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Octagon Capital Advisors LP holds 870,000 shares of VRDN stock, worth $14 Million. This represents 3.72% of its overall portfolio holdings.
Number of Shares
870,000
Previous 870,000
-0.0%
Holding current value
$14 Million
Previous $19.8 Million
15.74%
% of portfolio
3.72%
Previous 4.78%
Shares
5 transactions
Others Institutions Holding VRDN
# of Institutions
200Shares Held
79.4MCall Options Held
477KPut Options Held
917K-
Black Rock Inc. New York, NY4.77MShares$76.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.6MShares$73.7 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.52MShares$72.5 Million3.82% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$62.3 Million12.28% of portfolio
-
State Street Corp Boston, MA3.52MShares$56.5 Million0.0% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $640M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...